Latest News
I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy
14 October 2019 - German biopharma company MorphoSys AG (FSE:MOR) (Nasdaq:MOR) stated that I-Mab Biopharma has received Investigational New Drug (IND) clearances from the National Medical Products Administration (NMPA) of China to expand the ongoing ...
OssDsign wins US FDA marketing clearance for Cranial PSI Accessories
14 October 2019 - Swedish medical company OssDsign AB (publ) reported on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance (K190523) to market its Cranial PSI Accessories in the US.The company said the Cranial PSI Accessori...
The FDA approves new migraine treatment Reyvow
14 October 2019 - Public health agency The US Food and Drug Administration announced on Friday that it authorised the marketing of Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory...
Topcon Healthcare to aid in transition of IBM's Merge Eye Station and Merge Eye Care PACS customers
14 October 2019 - Eye care software company Topcon Healthcare Solutions revealed on Friday that it has signed a partnership to support the transition plan of IBM Watson Health Imaging's Merge Eye Station digital fundus imaging platform and Merge...
Sobi announces start of tender offer for all outstanding shares of Dova Pharmaceuticals at USD27.5 per share
14 October 2019 - Swedish Orphan Biovitrum AB (Sobi)(STO:SOBI), a specialised international biopharmaceutical company transforming the lives of people with rare diseases, announced on Friday the commencement of a tender offer through its indirect who...